Q517--Radiopharmaceutical Sole Source

The VA Maine Healthcare System (VAMHS) intends to award on a sole source basis pursuant to FAR 13. This requirement will include the provision of radiopharmaceutical products to the Togus VA. Salient Characteristics Vendor will provide the following: Radiopharmaceutical products as needed by the requesting facility. May consist of: TC-99M Sodium Pertechnetate Unit Dose, TC-99M Mebrofenin Kinevac (CCK), TC-99M MDP (Medronate), TC-99M Sulfur Colloid, TC-99M Macroaggregated Albumin (MAA), TC-99M Stannous DTPA (Pentate), Vent (50-90 MCI), Respirator Accessories (Ultravent), TC-99M Ceretec-WBC Label/Brain, TC-99M MAG 3 Renal Agent, Pyrophosphate Solution (PYP) Cold, TC-99m Cardiolite/Sestamibi, TC-99M Myoview/Tetrofosmin, GA67 Citrate (7 MCI per patient), TL210 Thallium Chloride (3 MCI per Patient), I-123 Diagnostic Cap (200 UCI), I-123 Diagnostic Cap (2 MCI), Indium I-III, WBC Labeling, and Hespan This Special Notice is NOT a request for competitive proposals. Parties may identify their interest, accompanied by supporting literature, to the Contracting Officer no later than April 27, 2023, Responses should be sent to [email protected]. Information received will be for the purpose of determining whether or not to conduct a competitive procurement. The determination to conduct a competitive procurement based on responses to this notice is solely within the discretion of the Contracting Officer.